134923-62-9

Usage

Uses

Used in Organic Synthesis:
N1-(2-methoxyethyl)-N1-methylbenzene-1,4-diamine is used as a reagent in organic synthesis for its ability to form various chemical compounds, contributing to the development of new materials and products.
Used in Pharmaceutical Production:
In the pharmaceutical industry, N1-(2-methoxyethyl)-N1-methylbenzene-1,4-diamine is used as an intermediate in the synthesis of active pharmaceutical ingredients, playing a crucial role in the development of new medications.
Used in Specialty Chemicals:
This diamine compound is utilized in the production of specialty chemicals, where its unique properties can be leveraged to create high-value products for specific applications.
Used in Dyes and Pigments Production:
N1-(2-methoxyethyl)-N1-methylbenzene-1,4-diamine is used as a potential intermediate in the manufacturing process of certain types of dyes and pigments, contributing to the coloration and performance of these products in various industries.

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 151951-34-7 N-(2-methoxyethyl)-N-methyl-4-nitroaniline 

Downstream Products

• 1008506-12-4 N′-(6-bromoquinazolin-2-yl)-N-(2-methoxyethyl)-N-methylbenzene-1,4-diamine 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

Discovery and optimization of a novel series of potent mutant B-Raf V600E selective kinase inhibitors

B-Raf represents an attractive target for anticancer therapy and the development of small molecule B-Raf inhibitors has delivered new therapies for metastatic melanoma patients. We have discovered a novel class of small molecules that inhibit mutant B-Raf

Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes

Diacylglycerol acyltransferase-1 (DGAT-1) is the enzyme that catalyzes the final and committed step of triglyceride formation, namely, the acylation of diacylglycerol with acyl coenzyme A. DGAT-1 deficient mice demonstrate resistance to weight gain on hig

PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.